Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Return on Sales (2020 - 2025)

Historic Return on Sales for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to 2265.8%.

  • Lyell Immunopharma's Return on Sales fell 9558000.0% to 2265.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 7989.83%, marking a year-over-year decrease of 49599200.0%. This contributed to the annual value of 5486.67% for FY2024, which is 37670200.0% down from last year.
  • Per Lyell Immunopharma's latest filing, its Return on Sales stood at 2265.8% for Q3 2025, which was down 9558000.0% from 5483.0% recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Return on Sales peaked at 0.23% during Q4 2022, and registered a low of 21395.33% during Q3 2022.
  • Its 5-year average for Return on Sales is 4480.9%, with a median of 2097.24% in 2023.
  • In the last 5 years, Lyell Immunopharma's Return on Sales tumbled by -213775900bps in 2022 and then soared by 192980900bps in 2023.
  • Over the past 5 years, Lyell Immunopharma's Return on Sales (Quarter) stood at 16.73% in 2021, then surged by 99bps to 0.23% in 2022, then crashed by -1721920bps to 4032.62% in 2023, then tumbled by -342bps to 17838.82% in 2024, then surged by 87bps to 2265.8% in 2025.
  • Its last three reported values are 2265.8% in Q3 2025, 5483.0% for Q2 2025, and 7643.57% during Q1 2025.